ITB-MED is developing the proprietary antagonistic CD2-directed monoclonal antibody, TCD601 (siplizumab), for several indications. ITB-MED is wholly committed to advancing and exploring the potential of TCD601, with a particular focus on its applications in transplantation and autoimmunity. The efforts extend to comprehensive worldwide clinical trials. ITB-MED is actively investigating further preclinical therapies to expand the reach of its novel immune-modulating approaches.
View Top Employees from ITBMed| Website | http://itb-med.com/ |
| Revenue | $600000 |
| Employees | 39 (24 on RocketReach) |
| Founded | 2016 |
| Address | 110 E 59th St, Fl 28, New York City, New York 10022, US |
| Phone | +46 8 410 028 87 |
| Technologies |
JavaScript,
HTML,
PHP
+18 more
(view full list)
|
| Industry | Biotechnology, Biotechnology Research, Drug Manufacturing & Research, Transplantation Surgery, Pharmaceuticals, Science and Engineering, Immunology, Healthcare, Pharmaceutical, Monoclonal antibodies, Health Care |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 325414 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular ITBMed employee's phone or email?
ITBMed Questions
The ITBMed annual revenue was $600000 in 2024.
Alan Slade is the Senior Vice President, Global Head Clinical Development of ITBMed.
24 people are employed at ITBMed.
ITBMed is based in New York City, New York.
The NAICS codes for ITBMed are [32541, 325414, 3254, 32, 325].
The SIC codes for ITBMed are [28, 283].
Top ITBMed Employees
-
23
-
42
-
5
-
53
-
43
-
55+
-
1
-
ViewNick Hryciw
Associate Director, Clinical Operations at ITBMed
Los Angeles, California, United States35+
Related Companies
